In conclusion, the expression levels of circulating H19 and SPRY4‐IT1 lncRNAs in breast cancer patients could consider as the prognostic biomarkers and therapeutic targets in breast cancer, because of their excellent power in discriminating breast cancer from healthy individuals and the significant correlation of H19, and SPRY4‐IT1 lncRNAs with clinicopathological traits. This evidence concerns the gene H19 and breast carcinoma.